ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 9| Issue: 6| June 2023|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2023: 8.224 || ISI Value: 1.188

ANTI-VIRAL ACTIVITY OF FLOUROQUINOLONES

Parikshit Nagda*[1], Pari Vyas[2], Aina Bhati[3], Shivang Thakur[4], Diva Chouhan[5], Priyanshee Dodeja[6]

[1]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*
[2]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*
[3]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*
[4]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*
[5]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*
[6]*Pharm.D Scholar, Bhupal Nobles College of Pharmacy, Udaipur, Rajasthan*

ABSTRACT

This article investigates the antiviral characteristics of fluoroquinolones, a group of antibacterial agents, against diverse viral pathogens. Research findings indicate that fluoroquinolones like ciprofloxacin, ofloxacin, and levofloxacin demonstrate effectiveness in managing infections caused by hepatitis C virus (HCV) and BK virus in individuals who have undergone organ transplantation. However, the therapeutic efficacy of these antibiotics may be constrained in patients with advanced liver cirrhosis. Furthermore, fluoroquinolones have exhibited inhibitory effects on viral replication in experimental laboratory settings.

KEYWORDS- ***flouroquinolones, antiviral, HIV-AIDS, SARS-CoV-2, MERS-CoV, Hepatitis, influenza.***

INTRODUCTION

Fluoroquinolones have exhibited promising antiviral capabilities against a diverse array of viruses; nevertheless, their efficacy is contingent upon the specific viral strain and the patient's clinical condition. To comprehensively comprehend the potential of fluoroquinolones as antiviral agents, further scientific inquiry is imperative.

Regarding their application in HIV-AIDS, fluoroquinolones manifest exceptional antibiotic efficacy alongside advantageous pharmacokinetic properties. Nonetheless, their extensive utilization has engendered the emergence of antimicrobial resistance. Fluoroquinolones exhibit heightened inhibitory activity against bacteria at elevated concentrations, thereby impeding bacterial proliferation.

Fluoroquinolones, such as ciprofloxacin, ofloxacin, and levofloxacin, exhibit antiviral properties against various viruses. Studies have shown that these fluoroquinolones are effective in treating single-stranded RNA HCV (hepatitis C virus). In patients with HCV-induced chronic hepatitis and compensated liver cirrhosis, ofloxacin treatment for one to eight weeks resulted in a decrease in HCV RNA levels. Similarly, ciprofloxacin treatment in patients with chronic HCV showed no significant change in HCV RNA levels. However, it is worth noting that the efficacy of anti-HCV fluoroquinolones may be limited in patients with advanced liver cirrhosis(1).

In transplant patients with active BK virus replication, gatifloxacin treatment led to a reduction in viremia for two months. Additionally, ciprofloxacin treatment in kidney transplant patients with persistent BK infection resulted in the complete clearance or significant reduction of the virus load. Fluoroquinolones have shown inhibitory effects on viral replication in laboratory settings.

Recent clinical studies suggest that fluoroquinolone treatment, specifically with ciprofloxacin, may be beneficial for polyomavirus BK infections in transplant patients. Furthermore, ofloxacin and levofloxacin have demonstrated inhibitory effects on the topoisomerase activity of the vaccinia virus. However, they do not exhibit the same effects on herpes simplex virus and influenza virus.

Quinolones, including levofloxacin, have been found to inhibit rhinovirus (RV) infection by targeting cellular functions necessary for viral replication. Levofloxacin pretreatment reduces the number of acidic endosomes involved in RV RNA entry into the cytoplasm. Moreover, it inhibits the activation of nuclear factor kB proteins, contributing to the overall reduction of RV infection. Levofloxacin achieves this by modulating airway inflammation and reducing ICAM-1 expression levels.

It is important to note that the antiviral efficacy of fluoroquinolones, apart from levofloxacin, has not been extensively studied in the context mentioned above.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 9| Issue: 6| June 2023|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2023: 8.224 || ISI Value: 1.188

Overall, fluoroquinolones have demonstrated promising antiviral activities against various viruses, but their effectiveness may vary depending on the specific viral strain and the patient's condition. Further research is needed to fully understand the potential of fluoroquinolones as antiviral agents.

Flouroquinolones in HIV-AIDS

Fluoroquinolones are highly effective antibiotics with many advantageous pharmacokinetic properties. However, their extensive use has led to the development of antimicrobial resistance. Fluoroquinolones exhibit greater inhibitory activity against bacteria at higher concentrations, which helps in inhibiting bacterial growth.

In the human body, when human lymphocyte CEM cell lines are infected with HIV-1, it results in cell death. However, fluroquinolones protect the infected cells from HIV-1-mediated cytolysis.

Some examples of fluoroquinolones include ciprofloxacin, norfloxacin, and enoxacin.

Infection of human lymphocytes CEM cell lines with HIV-1 (Human Immunodeficiency Virus 1, LAV-1 strain) leads to cell death. The D-isomer of floxacin is approximately 50 times less effective than the I-isomer. Almost none of the rescued cells showed detectable HIV antigens. All surviving cells have lost the expression of the CD4 antigen. The rescued CEM and MT4 cells remain stable and do not require continuous drug expression for survival(2).

Care must be taken when using invitro drugs, including fluoroquinolones. Continuous vigilance is necessary to monitor adverse drug reactions in patients with HIV and AIDS.
Infection of human lymphocyte CEM cell lines with HIV-1 (Human Immunodeficiency Virus type-1, LAV-1 strain) leads to cell death. Ofloxacin, a fluoroquinolone antibiotic, has shown protective effects against HIV-1-mediated cytolysis in infected cells. Other fluoroquinolones such as ciprofloxacin, norfloxacin, and enoxacin also exhibit similar protection against HIV-1-mediated cytolysis. Furthermore, novel arylpiperazinyl fluoroquinolones have been reported(2).

In the study of structure-activity relationships (SAR), it was found that the aryl substituents on the piperazine nitrogen play a crucial role in the anti-HIV-1 activity. Several compounds demonstrated potent anti-HIV activity, with an IC50 value of 0.06μM in chronically infected cells.

The risk of recurrent nontyphoid Salmonella (NTS) bacteremia and the trends of antimicrobial resistance in NTS among HIV-infected patients receiving highly active antiretroviral therapy (HAART) are currently unknown. In conclusion, the risk of recurrent NTS bacteremia has significantly decreased in the HAART era. However, NTS isolates obtained from HIV-infected patients are increasingly showing resistance to fluoroquinolones. Therapeutic drug monitoring of fluoroquinolones is beneficial in ensuring that maximum Cmax to MIC ratios are achieved, particularly in patients at risk for malabsorption, such as those infected with HIV.

Antiviral Activity against SARS-CoV-2 and MERS-CoV

Interferon Therapy in SARS, MERS, and COVID-19 Patients. COVID-19, caused by the novel SARS-CoV-2 virus, has become an epidemic, posing a significant burden on human health. Interferon (IFN) is a natural substance that helps the body's immune system fight against viral infections, particularly those caused by alpha and beta viruses. However, recent clinical trials have shown no benefits of IFN therapy in COVID-19(3).

SARS-CoV-2 (Severe Acute Respiratory Syndrome) is the causative agent of COVID-19 disease. It was first identified as infecting humans in 2019. The virus spreads from person to person through coughing and talking of infected individuals.

MERS-CoV-2 (Middle East Respiratory Syndrome) is an infectious and sometimes fatal respiratory illness. It is often transmitted through close contact with infected patients.

The role of fluoroquinolone drugs in COVID-19:
Fluoroquinolones have demonstrated antiviral activity against various viruses, including vaccinia virus, HSV-1, HSV-2, HCV, and HIV. Recent studies have indicated that fluoroquinolones such as ciprofloxacin and moxifloxacin may inhibit the replication of SARS-CoV-2 by exhibiting a stronger capacity for binding to protease compared to chloroquine and nelfinavir. Additionally, fluoroquinolones have shown multiple immune system modulatory actions, leading to a reduction in inflammatory response. Levofloxacin and moxifloxacin are considered effective therapeutic agents for managing pneumonia(3).

Fluoroquinolones in hepatitis and influenza

Fluoroquinolones, such as ofloxacin, should be used as first-line treatment for cystic fibrosis. Cyclophosphamide and all other drugs, except for prednisolone, which was increased to 20mg daily, were discontinued. Prolonged hepatitis is rare, and the Committee on Safety of Medicines received 18 reports of liver disorders out of a total of 640 reports of adverse reactions to ofloxacin (personal communication with the Regional Drug and Therapeutic Committee). There have been a few case reports implicating ofloxacin in the induction of hepatitis among quinolones. Hepatitis C is an infection caused by a virus that attacks the liver. Fluoroquinolone antibiotics have antiviral properties against RNA viruses, including HCV. Hepatitis C is a common cause of chronic liver disease. Fluoroquinolones are effective antimicrobial agents in the treatment of conditions associated with liver failure, including portal systemic encephalopathy (PSE). They have also been reported to possess antiviral properties against both DNA and RNA viruses, including HCV(4).

Ciprofloxacin, ofloxacin, levofloxacin, and gatifloxacin have been found to be clinically effective in treating the single-stranded RNA HCV and the non-enveloped, encapsulated DNA polyomavirus BK.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 9| Issue: 6| June 2023|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2023: 8.224 || ISI Value: 1.188

MECHANISM OF ACTION OF ANTI-VIRAL ACTIVITY OF FLOUROQUINOLONES

Fluoroquinolones, a class of antibiotics, exhibit antiviral effects against specific viruses. While they primarily target bacteria, their antiviral activity operates through various means. Here are several suggested mechanisms through which fluoroquinolones demonstrate their antiviral properties:

1. Inhibition of viral replication enzymes: Fluoroquinolones can impede the activity of viral enzymes responsible for replication. They might hinder viral DNA or RNA polymerases, crucial for viral reproduction. By obstructing these enzymes, fluoroquinolones hinder the virus's ability to multiply and disseminate.
2. Disruption of viral DNA synthesis: Fluoroquinolones disrupt the production of viral DNA. They can hinder the functioning of topoisomerases, enzymes engaged in DNA replication and repair. By interfering with topoisomerases, fluoroquinolones can cause DNA breaks, preventing efficient viral replication.
3. Modulation of host immune response: Fluoroquinolones may exert immunomodulatory effects, influencing the host's immune response to viral infections. They can impact the production and release of various cytokines, essential signaling molecules in immune responses. By regulating cytokine levels, fluoroquinolones potentially modulate the immune system's ability to combat viral infections.
4. Indirect antiviral effects: Fluoroquinolones can indirectly exhibit antiviral effects by targeting bacteria that can worsen viral infections. In certain cases, bacterial infections contribute to the severity or complications of viral infections. By eliminating or controlling bacterial infections, fluoroquinolones indirectly improve the outcome of viral infections.

CONCLUSION

In conclusion, fluoroquinolones demonstrate significant potential as antiviral agents, exhibiting promising efficacy against a variety of viral pathogens. However, further extensive investigation is necessary to comprehensively grasp their effectiveness and determine their specific effectiveness against diverse viral strains and varying patient conditions. This research should delve into the intricate mechanisms through which fluoroquinolones interact with viral targets and investigate their impact on viral replication and infection. Moreover, studies should encompass a wider range of viral strains and patient cohorts to establish the universality of fluoroquinolones' antiviral properties. By deepening our understanding of the potential advantages and constraints of fluoroquinolones in combating viral infections, we can enhance the advancement of efficacious treatment strategies and optimize patient outcomes.

REFERENCES

1. *Dalhoff A. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis. 2015;34(4):661–8.*
2. *Nozaki-Renard J, Iino T, Sato Y, Marumoto Y, Ohta G, Furusawa M. Fluoroquinolones Protect the Human Lymphocyte CEM Cell Line from HIV-1-Mediated Cytotoxicity. Cell Struct Funct. 1990;15(5):295–9.*
3. *Viruses | Free Full-Text | Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV [Internet]. [cited 2023 Jun 19]. Available from: https://www.mdpi.com/1999-4915/13/1/8*
4. *Kojima H, Kaita KDE, Hawkins K, Uhanova J, Minuk GY. Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure. Antimicrob Agents Chemother. 2002 Oct;46(10):3280–2.*